Melanie Davies, Professor of Diabetes Medicine at University of Leicester, Honorary Consultant Diabetologist at University Hospitals of Leicester NHS Trust and Principal Investigator for VISTA said: Despite huge progress in the field of obesity management, significant opportunity remains to deliver broader, sustainable and more meaningful health benefits for the billions of people living with obesity or weight-related complications.The VISTA results show that people receiving once-daily oral elecoglipron achieved significant weight loss as well as lower blood pressure and systemic inflammation, demonstrating its potential to treat both obesity and its related complications. Vanita Aroda, Director of Diabetes Clinical Research at Brigham and Women's Hospital, Associate Professor at Harvard Medical School and Principal Investigator for SOLSTICE, said: In the SOLSTICE trial, the significant HbA1c and weight loss results achieved with elecoglipron show its potential to become an important treatment option for people with type 2 diabetes
compounding pharmacies to meet individual needs
Metabolic activation of intrahepatic CD8 + T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes
Elkind-Hirsch KE, Chappell N, Shaler D, Storment J, Bellanger D (2022) Liraglutide 3 mg on weight, body composition, and hormonal and metabolic parameters in women with obesity and polycystic ovary syndrome: a randomized placebo-controlled-phase 3 study
